Department of Respiratory and Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Province People's Hospital, China.
Department of Internal Medicine, Cheng Du Aerospace Hospital, China.
J Coll Physicians Surg Pak. 2020 Mar;30(3):332-334. doi: 10.29271/jcpsp.2020.03.332.
The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection. It was an experimental study carried out from April 2016 to September 2018. One hundred and fourteen patients with multi-drug resistant acinetobacter baumannii pulmonary infection were randomly divided into group A and group B with 57 cases in each group. Group A was treated with cefoperazone-sulbactam sodium alone, and group B was treated with cefoperazone-sulbactam combined with tigecycline. After 14 days of treatment, serum levels of PCT, CRP, TNF-a and IL-6 in group B were lower than those in group A (all p <0.001); APACHE II scores of group B were lower than those of group A (p <0.001). Compared with cefoperazone-sulbactam sodium alone, cefoperazone-sulbactam combined with tigecycline can effectively reduce the inflammatory response of patients with multi-drug resistant acinetobacter baumannii pulmonary infection; and thus a better prognosis can be obtained.
本研究旨在比较头孢哌酮舒巴坦单用与联合替加环素治疗多重耐药鲍曼不动杆菌肺部感染的疗效。这是一项 2016 年 4 月至 2018 年 9 月进行的实验研究。将 114 例多重耐药鲍曼不动杆菌肺部感染患者随机分为 A 组和 B 组，每组 57 例。A 组给予头孢哌酮舒巴坦钠单用，B 组给予头孢哌酮舒巴坦联合替加环素治疗。治疗 14 天后，B 组患者血清 PCT、CRP、TNF-a 和 IL-6 水平均低于 A 组（均 P<0.001）；B 组患者的 APACHE II 评分低于 A 组（P<0.001）。与头孢哌酮舒巴坦钠单用相比，头孢哌酮舒巴坦联合替加环素可有效降低多重耐药鲍曼不动杆菌肺部感染患者的炎症反应，从而获得更好的预后。
